OUTCOME OF PRP TREATMENT IN PATIENTS WITH INFRAORBITAL DARK CIRCLES

Main Article Content

Ramla Moughal
Rabia Ghafoor
Maria Naseer
Hadia Akram
Vinesha Devi
Alina Ahmed

Keywords

Platelet-rich plasma, infraorbital dark circle, Facial skin rejuvenation, success outcomes.

Abstract

Infraorbital dark circles are not medically significant, but they are unsightly for many people, especially women, and can arise at any age. PRP speeds wound healing and tissue regeneration.


Objective: To determine outcome of PRP treatment in patients with infraorbital dark circles.


Study Design: This Descriptive study was held in the Dermatology Department of JPMC, Karachi from 31st December 2020 to 30th June 21.


Methods: Patients gave verbal agreement to prospectively collect data. 76 diagnostically qualified patients were included. Quantitative data was given as standard deviation and mean and qualitative factors as percentages and frequency. To determine how effect modifiers affected the result variable, stratification was used. Post stratification chi square test was applied taking p-value ≤0.05 as significant.


Results: This study comprised 76 patients who met inclusion and exclusion criteria. The average age and duration of dark circles in our study were 47.14±8.49 years and 5.72±2.24 months. There were 62 (81.6%) successful outcomes and 14 (18.4%) unsuccessful outcomes.


Conclusion: Platelet-rich plasma improves infraorbital dark circles and is best and noninvasive.

Abstract 371 | PDF Downloads 161

References

1. Sarkar R, Ranjan R, Garg S, Garg VK, Sonthalia S, Bansal S. Periorbital Hyperpigmentation: A Comprehensive Review. J Clin Aesthet Dermatol. 2016 Jan;9(1):49–55.
2. Freitag FM, Cestari TF. What causes dark circles under the eyes? Journal of Cosmetic Dermatology. 2007 Sep;6(3):211–5.
3. Park SR, Kim HJ, Park HK, Kim JY, Kim NS, Byun KS, et al. Classification by causes of dark circles and appropriate evaluation method of dark circles. Skin Res Technol. 2016 Aug;22(3):276–83.
4. Park KY, Oh IY, Moon NJ, Seo SJ. Treatment of infraorbital dark circles in atopic dermatitis with a 2790-nm erbium: yttrium scandium gallium garnet laser: a pilot study. J Cosmet Laser Ther Off Publ Eur Soc Laser Dermatol. 2013 Apr;15(2):102–6.
5. Mehryan P, Zartab H, Rajabi A, Pazhoohi N, Firooz A. Assessment of efficacy of platelet-rich plasma (PRP) on infraorbital dark circles and crow’s feet wrinkles. J Cosmet Dermatol. 2014 Mar;13(1):72–8.
6. Ahmed NA, Mohammed SS, Fatani MI. Treatment of periorbital dark circles: Comparative study of carboxy therapy vs chemical peeling vs mesotherapy. J Cosmet Dermatol. 2019 Feb;18(1):169–75.
7. Ellabban NF, Eyada M, Nada H, Kamel N. Efficacy and tolerability of using platelet-rich plasma versus chemical peeling in periorbital hyperpigmentation. J Cosmet Dermatol. 2019 Dec;18(6):1680–5.
8. Nguyen HT, Isaacowitz DM, Rubin PA. Age- and fatigue-related markers of human faces: An eye-tracking study. Ophthalmology. 2009;116:355–60.
9. Gendler EC. Treatment of periorbital hyperpigmentation. Aesthet Surg J. 2005;25:618–24.
10. Rohrich RJ, Pessa JE. The fat compartments of the face: Anatomy and clinical implications for cosmetic surgery. Plast Reconstr Surg. 2007;119:2219–27.
11. Pessa JE, Zadoo VP, Mutimer KL, Haffner C, Yuan C, DeWitt AI, et al. Relative maxillary retrusion as a natural consequence of aging: Combining skeletal and soft-tissue changes into an integrated model of midfacial aging. Plast Reconstr Surg. 1998;102:205–12.
12. Nakra T. Biplanar contour-oriented approach to lower eyelid and midface rejuvenation. JAMA Facial Plast Surg. 2015;17:374–81.
13. Friedmann DP, Goldman MP. Dark circles: Etiology and management options. Clin Plast Surg. 2015;42:33–50.
14. Roh MR, Chung KY. Infraorbital dark circles: Definition, causes, and treatment options. Dermatol Surg. 2009;35:1163–71.
15. Epstein JS. Management of infraorbital dark circles. A significant cosmetic concern. Arch Facial Plast Surg. 1999;1:303–7.
16. Goldberg RA, McCann JD, Fiaschetti D, Ben Simon GJ. What causes eyelid bags? Analysis of 114 consecutive patients. Plast Reconstr Surg. 2005;115:1395–402.
17. Watanabe S, Nakai K, Ohnishi T. Condition known as “dark rings under the eyes” in the Japanese population is a kind of dermal melanocytosis which can be successfully treated by Q-switched ruby laser. Dermatol Surg. 2006;32:785–9.
18. Guerrero D. Dermocosmetic management of the red face and rosacea. Ann Dermatol Venereol. 2011;138(Suppl 3):S215–8.
19. Sidle DM, Decker JR. Use of makeup, hairstyles, glasses, and prosthetics as adjuncts to scar camouflage. Facial Plast Surg Clin North Am. 2011;19:481–9.
20. Bierman A, Figueiro MG, Rea MS. Measuring and predicting eyelid spectral transmittance. J Biomed Opt. 2011;16:067011.
21. Darlenski R, Surber C, Fluhr JW. Topical retinoids in the management of photodamaged skin: From theory to evidence-based practical approach. Br J Dermatol. 2010;163:1157–65.
22. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20:308–13.
23. Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Venereol. 2006;20:781–7.
24. Garcia A, Fulton JE., Jr The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg. 1996;22:443–7.
25. Amnuaikit T, Maneenuan D, Boonme P. Evaluation of caffeine gels on physicochemical characteristics and in vivo efficacy in reducing puffy eyes. J Appl Pharm Sci. 2011;1:56.

Most read articles by the same author(s)